Omalizumab
Brand: Xolair®
NICE TA: 339
Indication: Chronic spontaneous urticaria (NICE TA339)
Disease category: Skin
Commissioning responsibility: CCG
PbR excluded: Yes
Background
Omalizumab is recommended as an option as add‑on therapy for treating severe chronic spontaneous urticaria in adults and young people aged 12 years and over only if:
• the severity of the condition is assessed objectively, for example, using a weekly urticaria activity score of 28 or more
• the person’s condition has not responded to standard treatment with H1‑antihistamines and leukotriene receptor antagonists
• omalizumab is stopped at or before the fourth dose if the condition has not responded
• omalizumab is stopped at the end of a course of treatment (6 doses) if the condition has responded, to establish whether the condition has gone into spontaneous remission, and is restarted only if the condition relapses
• omalizumab is administered under the management of a secondary care specialist in dermatology, immunology or allergy
• the company provides omalizumab with the discount agreed in the patient access scheme.
Recommendation
LMMG recommendation: Red
Click here to find the definitions for the colour classifications
Reason for decision: Specialist medicine
Supporting documents:
NICE TA339 - Omalizumab for previously treated chronic spontaneous urticaria
Decisions of Lancashire local decision making groups:
| NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
|---|---|---|---|---|---|
Red |
Red |
Red |
Red |
Red |
Red |
